Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

PathAI Launches PathExplore™ Fibrosis: An AI-Powered Pathology Breakthrough in Fibrosis, Collagen, and Fiber Quantification Directly from Whole Slide Images

PathAI

PathAI, a leader in AI-powered pathology solutions, is proud to introduce PathExplore™ Fibrosis 1 on our AISight® Translational Research platform, a one-of-a-kind AI tool designed to revolutionize fibrosis, collagen, and fiber quantification directly from whole-slide images (WSIs) of hematoxylin and eosin (H&E)-stained tissue. PathExplore™ Fibrosis offers an unprecedented ability to analyze morphology and spatial organization of fibrosis in the tumor microenvironment (TME) directly from routine pathology images at scale, providing new insights into tumor biology and therapeutic response. Fibrosis and collagen fibers are emerging as crucial biomarkers and drug targets due to their potential roles in cancer progression, metastasis, and immune response. Leveraging advanced machine learning techniques, PathExplore™ Fibrosis offers scalable, rapid analysis, making it a transformative tool in oncology translational research. PathAI’s solution facilitates this analysis directly from routine H&E pathology images from standard imaging platforms, democratizing access to key insights into tumor biology and therapeutic responses without the need of custom microscopy. "What began as internal research by our scientific team has evolved into a powerful tool for cancer researchers, enabling them to explore previously inaccessible aspects of tumor morphology," said Ben Glass, VP of Product and Translational Research at PathAI. "Fibrosis is increasingly recognized as a potentially important biomarker in cancer research. By making it possible to study this directly from routine H&E images, we’re providing researchers with the means to scale their understanding of disease biology, evaluate drug efficacy, and drive the development of new fibrosis-related therapies." “By combining the cell and tissue features provided by PathExplore™ 2 with collagen and fibrosis measurements from PathExplore™ Fibrosis, researchers now have access to an unprecedented multidimensional view of the TME,” said Eric Walk, M.D., FCAP, chief medical officer at PathAI. “From a single image, researchers can ask and answer new questions about the organization and morphology of fibrosis in the TME and how this inhibits or promotes cancer progression.” PathAI will be presenting novel findings utilizing PathExplore™ Fibrosis and the underlying technology at the upcoming Society of Immunotherapy of Cancer conference (SITC 2024) on November 6-11, 2024, in Houston, Texas. Be one of the first to access PathExplore™ Fibrosis by reaching out to us at bd@pathai.com or access our self-serve demo of PathExplore™ Fibrosis for hands-on experience here. SITC 2024 Abstracts #1378: Stromal collagen features from H&E-stained whole slide images are associated with lymphocyte infiltration and survival following checkpoint inhibition in patients with non-small cell lung cancer - in collaboration with Incendia Therapeutics #88: Machine learning-based collagen fiber quantification enables analysis of the pancreatic cancer tumor microenvironment directly from hematoxylin and eosin-stained whole slide images Footnotes 1: PathExplore™ Fibrosis is for research use only. Not for use in diagnostic procedures. 2: PathExplore™ is for research use only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples, with the potential to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

November 04, 2024 10:00 AM Eastern Standard Time

ETFs: A Streamlined Approach to Sector-Specific Investment

Select Sector SPDR

In the dynamic world of financial markets, the Select Sector SPDR ETFs offer a practical method for investors seeking sector-specific investments. By segmenting the S&P 500 into defined sectors, these ETFs present both individual and institutional investors with an opportunity to build more targeted and strategic investment portfolios. Select Sector SPDR ETFs are designed to cater to various segments of the economy, allowing investors to concentrate their investments based on specific economic sectors, aligned with their investment goals, risk tolerance, and market perspectives. Overview of the available Select Sector SPDR ETFs Communication Services Select Sector SPDR Fund (XLC) is centered around telecommunications and media companies. Consumer Discretionary Select Sector SPDR Fund (XLY) is comprised of companies involved in non-essential goods and services focused on luxury items, automobiles, and hotels. Consumer Staples Select Sector SPDR Fund (XLP) is primarily essential consumer goods and services like beverages, clothing, and personal products. Energy Select Sector SPDR Fund (XLE) is focused on the energy sector which includes oil and natural gas industries. Financials Select Sector SPDR Fund (XLF) includes banking, capital markets, and insurance industries. Health Care Select Sector SPDR Fund (XLV) is dedicated to pharmaceuticals, healthcare equipment, and biotechnology. Industrials Select Sector SPDR Fund (XLI) encompasses manufacturing, construction, and aerospace companies. Materials Select Sector SPDR Fund (XLB) focuses on mining, construction materials, and packaging sectors. Real Estate Select Sector SPDR Fund (XLRE) looks into commercial real estate services and Real Estate Investment Trusts (REITs), excluding Mortgage REITs. Technology Select Sector SPDR Fund (XLK) is focused on the information technology, semiconductor, and electronics industries. Utilities Select Sector SPDR Fund (XLU) centers around electricity and natural gas companies. The Select Sector SPDR ETFs provide an uncomplicated and transparent way to navigate sector-specific investments, allowing investors to adjust their strategies in response to ever-changing market dynamics. This sector-focused approach can provide detailed analysis and strategic portfolio management, offering a valuable tool for investors to fine-tune their investment allocations. As the ETF landscape continues to evolve, the Select Sector SPDR provides a mechanism for investors aiming to fine tune their investment strategies through focused sector allocations. This structured investment avenue supports the development of robust and adaptive portfolios, tailored to meet diverse investor needs and market conditions. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007907 EXP 12/31/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

November 01, 2024 05:00 AM Eastern Daylight Time

VIZIA Diagnostics Selects PathAI and the AISight Image Management System to Support the Transition to Digital and AI-Powered Pathology

PathAI

PathAI, a leader in digital and AI-powered pathology solutions, and VIZIA Diagnostics, a GI- specialized pathology laboratory based in Alpharetta, Georgia, have announced that VIZIA has adopted PathAI’s AISight Ⓡ1 Image Management System (IMS) and AI technology to advance the precision and operational efficiency of its pathology services. In today’s rapidly evolving pathology landscape, independent labs face increasing pressure to provide timely and accurate assessments. To meet these demands, VIZIA Diagnostics conducted a thorough evaluation of digital pathology solutions and selected PathAI’s AISight Image Management System as the ideal platform. AISight’s robust workflow optimization, advanced case management, and broad applicability across various use cases were key factors in the decision. By integrating AISight with algorithm products, VIZIA Diagnostics aims to improve turnaround times for their clients and deliver even higher-quality pathology services. "AISight offers more than just efficiency; it empowers us to lead in the evolving field of gastrointestinal pathology," said Gregg Costantino, CEO of VIZIA Diagnostics. "By streamlining our workflows and enhancing accuracy, we're able to deliver faster, more precise results for our clients. This collaboration aligns with our commitment to being a flexible and quality-focused partner, providing exceptional service and care in the GI space, and positioning us at the forefront of digital and AI pathology." "The transformative potential of AI and Digital Pathology, coupled with the growing need for business-critical solutions our pathologists and GI providers require, was at the forefront of our decision to adopt this system," added Ed Cochrane, commercial director of VIZIA Diagnostics. “PathAI’s platform provides us unmatched agility and responsiveness for the dynamic landscape of anatomic pathology and our diverse customer base”. "The selection of PathAI by VIZIA Diagnostics reflects our shared commitment to improving patient outcomes through innovative, digital, and AI-powered pathology solutions," said Andy Beck, MD, PhD, co-founder and CEO of PathAI. "By adopting these technologies, VIZIA Diagnostics is well-positioned to meet the growing demand for more efficient, high-quality pathology operations. We are excited to support them as they embark on their digital journey to transform their pathology services." AISight is a cloud-native, intelligent enterprise workflow solution trusted by pathologists worldwide. As a centralized platform for case management, workload balancing, and image management, AISight seamlessly integrates best-in-class artificial intelligence tools from PathAI and third-party partners. This comprehensive approach will enable VIZIA Diagnostics to address a broad spectrum of histopathology use cases efficiently and consistently. Footnote 1. AISight is for Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming workflow and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit www.pathai.com. About VIZIA Diagnostics VIZIA Diagnostics is an established leader in gastrointestinal pathology, dedicated to advancing diagnostic services through enhanced processes and exceptional patient care. As a vital partner in healthcare, VIZIA leverages advanced, modern technology and the expertise of its dedicated team to deliver accurate, timely, and reliable results. Focused on setting new industry standards, VIZIA's experts ensure that these advanced solutions elevate the quality of GI diagnostics and improve patient outcomes. For more information on VIZIA Diagnostics, please visit www.viziadx.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

October 31, 2024 10:00 AM Eastern Daylight Time

Intus Care to Host Virtual Roundtable on “PACE & The Future of Healthcare Data Interoperability”

Intus Care

Intus Care, a technology leader in the PACE market, will host a virtual conversation on “PACE and the Future of Healthcare Data Interoperability” with prominent guests within healthcare and the PACE (Programs of All-Inclusive Care for the Elderly) community. Intus Care Cofounder and CEO Robbie Felton will moderate a discussion among Shawn Bloom, CEO and president of the National PACE Association (NPA); Dr. David Feinberg, Chairman of Oracle Health (formerly CEO of Cerner); and Stephanie Rock, Vice President of Product at Intus Care. The discussion will center around healthcare system interoperability, the importance of interoperability, and the current interoperability challenges that remain. In particular, the conversation will focus around: What can the PACE community learn from modern interoperability standards by the broader value-based care community? Why does PACE need an interoperable and modular technology strategy as the model expands? The hour virtual roundtable is scheduled for Thursday, November 14 at 1 p.m. ET. Anyone interested in interoperability, healthcare, and PACE is invited to listen to the discussion. Registration is open now. PACE is a “comprehensive, fully integrated, provider-based health plan for the frailest and costliest members of our society – those who require a nursing home level of care,” according to the National PACE Association. The goal, however, is to provide care that allows those enrolled to continue living at home and in their communities. Nationally, 95% of participants continue to live at home. The model is now considered the gold standard for seniors with complex care needs. According to the NPA, there are currently 178 PACE programs serving more than 78,500 participants in 33 states and the District of Columbia. As the U.S. population ages – adults 65 years or older will increase 30%, from 63 million to 82 million, accounting for nearly one-quarter of the U.S. population by 2050 – the need for PACE to expand will only increase. To scale effectively, PACE organizations need technology that meets their needs, including a unified documentation system that integrates and shares data securely and seamlessly. "The future of interoperability in PACE lies in seamless data sharing across care teams, empowering providers to deliver truly coordinated, patient-centered care," said Felton. "While progress has been made, there are still regulatory and technological hurdles for this to be truly realized for PACE organizations, but its realization will unlock unprecedented value and transform how we care for our aging population. I look forward to unpacking this with our esteemed guests for the virtual fireside chat." Registration for the virtual roundtable is open now. A recording will be available following the event for individuals unable to attend live. About Intus Care Intus Care creates technology and services for PACE and value-based care organizations to achieve operational efficiency and better clinical and financial outcomes. Intus Care currently works with over 60 PACE programs across 16 states. Visit our website to learn more at intuscare.com. Contact Details SVM Public Relations +1 401-490-9700 intuscare@svmpr.com Company Website https://www.intuscare.com/

October 31, 2024 10:00 AM Eastern Daylight Time

CONSENSUS HEALTH CHIEF EXECUTIVE OFFICER MICHAEL LOVETT NAMED 2024 EXECUTIVE OF THE YEAR-FOR PROFIT CATEGORY BY NJBIZ IN BUSINESS OF THE YEAR AWARDS

Consensus Health

Consensus Health, a leading New Jersey-based healthcare organization with a physician-led medical group and an Independent Physician Alliance (IPA), announced today Chief Executive Officer Michael Lovett was named a 2024 Business of the Year—Executive of the Year (For-Profit category) honoree by NJBIZ. Annually, NJBIZ Business of the Year Awards recognize the state’s most dynamic companies and leaders who share a commitment to professional excellence, business growth and their communities. This year, more than 50 organizations and only three individuals will be honored for their significant contributions to helping the state’s business community grow and prosper. "This recognition reflects Mike’s exceptional focus on leading with integrity, fostering local impact, and elevating the patient experience. His approach resonates with our mission to build a collaborative environment where both patients and providers thrive. Mike’s leadership is a key asset to our value-based care journey, and we’re honored to celebrate this achievement with him,” shared Dr. Nedal Shami, chief executive officer of CareAbout Health, a value-based care managed services organization supporting Consensus Health. Lovett commented on the acknowledgement from NJBIZ: “This honor is a tribute to Consensus Health’s 700+ team of professionals who – each and every day – positively impact healthcare across New Jersey. It is their dedication and unrelenting care for our patients’ health and wellness that allows Consensus Health to stand out. “I want to extend my deepest gratitude to our team for their contributions, our leadership for their confidence in me and the judges who took note of our impact on elevating patient care statewide. It’s truly a privilege to accept this prestigious accolade on behalf of our entire growing enterprise,” Lovett concluded. The awards will be bestowed in a ceremony hosted by NJBIZ on Thursday, December 12, 2024 to be held at The DoubleTree by Hilton Somerset. About CareAbout Health CareAbout Health provides management, resources, value-add services, technology, and other support to its portfolio of medical groups and healthcare focused companies. CareAbout Health is helping align incentives to create a world where patients, providers, and payers work together in a seamless, coordinated manner toward common goals: higher quality, lower costs, better outcomes, and healthier communities. For more information, please visit www.careabout.com. About Consensus Health Marlton, New Jersey-based Consensus Health is a leading physician-owned and -governed medical group comprised of New Jersey-based independent primary care providers and specialty doctors. Consensus Health affords its 169 member physicians across 56 practices and 69 locations clinical autonomy, which enables them to focus on the delivery of high levels of patient care within the local markets they each serve. Currently, Consensus Health provides medical care statewide throughout 18 New Jersey counties. For more information, visit www.consensushealth.com or connect with the Company on LinkedIn. Contact Details PAIRELATIONS, LLC Susan J. Turkell +1 303-766-4343 sturkell@pairelations.com Company Website https://www.consensushealth.com/

October 30, 2024 08:00 AM Eastern Daylight Time

Avenue Z Launches New Public Affairs Practice to Help Clients Navigate Complexities of Modern Advocacy

Avenue Z

Avenue Z, a media and technology company, today announced the launch of its Public Affairs Group, a multidisciplinary, strategic practice designed to shape client outcomes in public and private advocacy, shareholder activism and ESG, philanthropy and civil society, and regulatory environments. In response to the growing power and control from big media companies and tech companies, Avenue Z’s new Public Affairs Group leverages a blend of communications, media, creative, and technology to affect meaningful change. The company’s approach supports clients to achieve consensus and desired outcomes by connecting highly targeted content to the right audiences at the right time, building trust. “The way the public is gaining information and forming perspectives has changed, and organizations need to engage their audiences across all channels in new ways,” said Nneka Etoniru, Avenue Z’s EVP of Global Brand Strategy and lead of the new Public Affairs Group. “Our solutions are uniquely positioned to help clients achieve lasting influence by guiding them through critical moments, enhancing their public image, and accomplishing their goals.” “Making a quantifiable impact in public affairs, akin to brand marketing or reputation management, requires both human and technology-informed approach,” said Jeffrey Herzog, Avenue Z founder and CEO. “Our strength lies in blending storytelling, media, and data to create influential connections across channels - from the Wall Street Journal to TikTok." Avenue Z’s Public Affairs practice is tailored to serve a diverse range of clients, including: Private Sector: Helping corporations gain consensus among decision-makers and standard bearers, secure contracts and public-private partnerships, and win necessary approval. Public Sector: Assisting municipal, state, and federal agencies with raising awareness, launching public health initiatives, combatting electoral misinformation, and developing educational campaigns across demographics. High-Profile Public Figures: Assisting in navigating public opinion, counter-influencing harassment campaigns, managing crises, and curating strategically engaging online conversations to protect their reputation. Charities and Philanthropies: Supporting non-profits in raising funds, advancing agendas, enhancing prestige, and navigating challenges to maximize organizational impact. Trade Organizations and Industry Groups: Helping industry-specific organizations advocate for their members' interests, inform external audiences on policy impact, and shape public perception of their industry. Along with the practice launch, Avenue Z has released an insightful trends report, offering a deep dive into the latest shifts shaping public policy and communication, helping organizations stay ahead of the curve. Public Affairs Trend Report 2024: Shaping Perception and Driving Outcomes in High-Stakes Environments covers trends impacting key sectors from healthcare to fintech, venture capital, emerging tech, manufacturing, and more. Read the full report, here. Avenue Z’s ability to lead high-stakes special situations is built on a foundation of expertise lasting more than 25 years. The company’s heritage dates back to 1998, when digital visionary and entrepreneur Jeffrey Herzog pioneered search engine marketing and later, sold iCrossing, his first digital media company, to Hearst Magazines for $450 million. Avenue Z is a media and technology company breaking traditional boundaries between marketing, advertising and PR to increase client revenue and elevate their reputation. From the Wall Street Journal to TikTok, PR to social and search, we create narratives that drive commerce, connections, and conversion, across all channels. With experts, tech and teams based in New York, Orlando, Miami and global reach - we drive influence. Visit www.avenuez.com Contact Details Avenue Z Rachael Zahn +1 407-637-2833 press@avenuez.com Company Website https://www.avenuez.com/

October 30, 2024 07:48 AM Eastern Daylight Time

News Release

NuggMD is Providing Free Medical Cannabis Evaluations to Veterans on Veterans Day

NuggMD

NuggMD, the nation's leading telemedicine platform for cannabis, today announced that it is providing free online medical marijuana evaluations to veterans from Nov. 7 to Nov. 11. Rates of PTSD range from 10% to 30% among war-time vets and 31% struggle with chronic pain. Additionally, according to the U.S. Department of Veterans Affairs, fewer than 50% of veterans in need of mental health treatment end up receiving it. While cannabis remains illegal federally, 38 states and several U.S. territories have legalized cannabis used to treat qualifying medical conditions, among them PTSD and chronic pain. “Every adult deserves the freedom to use cannabis. That is what we stand for,” said Bobby Brock, vice president of marketing at NuggMD. “We urge our peers in the cannabis industry to use their resources to help veterans, because serving in the armed forces is one of the most selfless, patriotic things an American can do. We also invite policymakers to take seriously the potential that cannabis may have to improve the quality of life of those who choose to enlist, both as they serve and after they return home.” The free evaluations will be offered to all veterans who reside in the 28 markets that NuggMD serves, and who provide valid proof of service and their state-issued identification. The applicable states are listed on NuggMD’s website, and veterans can secure their appointment using NuggMD’s on-demand platform from 8 AM to 10 PM in their local time zone. In addition to providing free evaluations to veterans, the company is also offering a 25% discount to the spouses of veterans, under the same conditions. Since its launch in 2016, NuggMD's affiliated medical cannabis practitioners have helped over two million patients connect with qualified medical cannabis doctors. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia. They've connected over 2,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit https://www.nuggmd.com. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

October 29, 2024 02:50 PM Eastern Daylight Time

Study Shows PayMedix Lowers Costs and Improves Access to Healthcare for All Members

PayMedix

Today PayMedix announced findings from a longitudinal analysis of member data that shows its zero-interest financing and healthcare payments solution successfully stems the rise in health insurance costs for its employer members by as much as 40% versus the national average. Further, its data revealed that subscribers are less likely to require in-patient hospital care and access care at similar rates across all credit score categories. The findings, part of a review of 2023 data from more than 45,000 active members over a 12-month period, is the most comprehensive analysis of the long-term benefits of PayMedix’s innovative payments solution, first introduced more than 10 years ago. Highlights from the study include: Medical trend beats national benchmarks – according to Milliman’s 2023 study, the one-year and two-year annualized medical trend nationally were 6.4% and 5.4% respectively, in contrast to trend of just 4.0% (one-year) and 3.1% (two-year) for PayMedix member employers What it means: PayMedix member rates are rising at an annual rate that is approximately 40% lower than the national average. Employers who use PayMedix are saving money for themselves and their employees Equitable access to care regardless of credit scores – the PayMedix analysis showed that in 2023, employee members with low credit scores (between 350 – 649) averaged the same number of annual claims as employee members with higher credit scores (between 650 – 850+) What it means: Employers who provide members access to zero-interest financing and flexible payment plans offered through PayMedix allow all employees to access care that fits their means and budgets Lower inpatient utilization – on average, 22% of all insurance claims represent hospital inpatient care, according to Milliman’s 2023 benchmark, but only 14% of PayMedix members’ claims were for in-patient care during the same period * What it means: Lower inpatient utilization keeps costs down for everyone and illustrates how PayMedix contributes to better outcomes. In addition, when looking at claims involving professional care (e.g., visits to primary care, etc.), PayMedix outpaces national benchmarks by 10%, with 48% of all claims vs. 38% nationally. This suggests employees are going to the doctor and avoiding the need for emergent care. * “Our data demonstrates what we have believed all along – together with employers and providers, PayMedix can break the cycle of out-of-control healthcare costs and fix our broken healthcare system by providing guaranteed zero-interest financing for employees and prompt full payments to providers,” said Tom Policelli, CEO, PayMedix. “We’ve shown that over time, PayMedix not only reduces costs, but improves equitable access to the healthcare system. Nearly 25% of PayMedix members would not qualify for commercial credit. We have proven that we can drive down cost for everyone when people can access care when they need it and not when they think they can afford it.” PayMedix provides complete, uncapped financing for all in-network allowed charges that any employee may owe to providers. All employees are automatically enrolled, and PayMedix pays all participating providers in full. The employees each get a simplified consolidated statement (a SuperEOB) each month and can arrange to pay it on terms that fit their budgets. Participating providers, in turn, are simply paid the full employee balance due automatically and therefore have no consumer bill to collect. “Our solution has allowed better access to healthcare for tens of thousands of employee subscribers by making it simpler, more affordable and more equitable,” said Brian Marsella, president of PayMedix. “Add to that the satisfaction and retention of our members, with a NPS score that is three times the industry average and we’re excited about the continued potential for PayMedix.” * Reference: 2023 Milliman Medical Index (MMI) Study. Percentage noted excludes pharmacy claims. About PayMedix PayMedix, which began as the financing arm of Wisconsin-based HPS over a decade ago, is the only company solving the problem of high out-of-pocket costs for everyone – providers, patients, employers, and TPAs. PayMedix is changing how people access, use, and pay for healthcare by guaranteeing payments to providers and financing for all patients. PayMedix has processed more than $5 billion in medical payments for hospital systems and physician practices and can be implemented with any benefit plan that is using any PPO or HMO network. Contact Details PayMedix Kaitlynn Cooney +1 609-351-5944 kcooney@brodeur.com Company Website https://paymedix.com

October 29, 2024 10:00 AM Eastern Daylight Time

Greg Olsen's Youth Inc. Expands with New Podcast Season and Upcoming Commerce Platform

Youth Inc.

Youth Inc., the first digital media network dedicated exclusively to youth sports content and commerce, today announced that Season Two of its popular Youth Inc. Podcast will launch on Wednesday, Oct. 30. Following the company’s 2024 $4.5 million seed funding round, led by Will Ventures, Youth Inc. is developing a new centralized hub blending news, original content, and retail for the youth sports market. Launched in 2022, Season One of the Youth Inc. Podcast featured conversations with iconic athletes like Jerry Rice, Russell Wilson, Jennie Finch, and Dale Earnhardt Jr. After a breakout debut season with more than 400,000 downloads, millions of impressions, and a nearly perfect viewership rating, Youth Inc. Is expanding its vision as it prepares to launch Season Two. Co-founded by Emmy Award-winning NFL analyst and Pro Bowl tight end Greg Olsen, former Fanatics executive Ryan Baise and Audacy, Inc.’s Tim Murphy, the podcast will feature acclaimed sports psychologist Dr. Michael Gervais as co-host, offering crucial insights for navigating today’s complex youth sports landscape. “While there are more than 30 million young athletes in our country today, there has never been a platform designed to speak directly to families, coaches, and players about the challenges of today’s current state of play,” said Olsen. “Season one taught us invaluable lessons, and we're excited to bring even more insights and depth in Season Two. Partnering with Dr. Gervais, we’ll provide our audience with the tools and knowledge to succeed, all while making the journey engaging and enjoyable." Season Two of the podcast will address the critical challenges young athletes face today including fostering resilience, managing the pressures of competition, and leveraging mindset training for long-term success. The six-episode season is presented by two Founding Partners: Players Health, a sports technology company offering digital risk management services and insurance products to ensure a secure environment for athletes, and MaxU, a cutting-edge platform providing personalized, 24/7 support to help young athletes build skills that enhance their mental performance and overall development. As Youth Inc. enhances its content offerings, it is also set to launch a robust commerce platform in early 2025, designed to further support young athletes and their families. Led by former Fanatics head of new ventures, Ryan Baise, the platform will offer a range of products and services tailored specifically for youth sports families and coaches. "The youth sports landscape is ripe for transformation, and we believe our platform will revolutionize how families access vital information and resources," said Baise. "Our aim is to create a comprehensive marketplace where parents, athletes, and coaches can discover rigorously vetted content and products that reflect the investment they make in their young athletes' futures." To listen to Season One of the Youth Inc. podcast (available on major podcast platforms, YouTube, and social media in both video and audio formats), watch the Season Two trailer or for more information, please visit Youth Inc. Youth Inc. is the first digital media network dedicated exclusively to youth sports content and commerce. Co-founded by NFL alum and Fox Sports broadcaster Greg Olsen, former Fanatics executive, Ryan Baise, and former Audacy and New York Times Co. executive, Tim Murphy, Youth Inc. provides parents, coaches, and athletes with expert-driven guidance and resources to navigate the evolving youth sports landscape. For more information, visit www.youth.inc or follow along on YouTube, Instagram, X, and TikTok. Contact Details Youth Inc. Jackson Gaskins jgaskins@hotpaperlantern.com

October 28, 2024 09:00 AM Eastern Daylight Time

1 2 3 4 5 ... 302